iShares Nasdaq BioTech ETF

IBB-Q

NASDAQ:IBB

143.22
4.27 (3.07%)

Analysis and Opinions about IBB-Q

Signal
Opinion
Expert
BUY
BUY
July 13, 2020

Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

Show full opinionHide full opinion

Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

TOP PICK
TOP PICK
July 9, 2020
Growth of biotech is expected to explode in a post-pandemic world. Longer term, aging population and growth of middle class are tailwinds. 27 bps expense ratio. Yield is 0.22%.
Show full opinionHide full opinion
Growth of biotech is expected to explode in a post-pandemic world. Longer term, aging population and growth of middle class are tailwinds. 27 bps expense ratio. Yield is 0.22%.
HOLD
HOLD
January 2, 2020
A very good biotech ETF. If you have it and you like it, stay with it. See what percentage of your portfolio it comprises. For a sector play, don't go above 5-6% of your portfolio. You want to invest in it, not day trade it with every move.
Show full opinionHide full opinion
A very good biotech ETF. If you have it and you like it, stay with it. See what percentage of your portfolio it comprises. For a sector play, don't go above 5-6% of your portfolio. You want to invest in it, not day trade it with every move.
PAST TOP PICK
PAST TOP PICK
October 18, 2019
(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.
Show full opinionHide full opinion
(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.
PAST TOP PICK
PAST TOP PICK
August 29, 2019
(A Top Pick Jun 20/19, Down 5%) A pick from his aggressive growth strategy, so you get more volatility. Sees support. If there's a 10% bump, then he'll sell.
Show full opinionHide full opinion
(A Top Pick Jun 20/19, Down 5%) A pick from his aggressive growth strategy, so you get more volatility. Sees support. If there's a 10% bump, then he'll sell.
TOP PICK
TOP PICK
June 20, 2019
Not for everybody. This is for the more aggressive mandates. The expense ratio is 47 basis points. This is for rapid trading. He thinks it will get to the $115 target.
Show full opinionHide full opinion
Not for everybody. This is for the more aggressive mandates. The expense ratio is 47 basis points. This is for rapid trading. He thinks it will get to the $115 target.
TOP PICK
TOP PICK
June 7, 2019
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
Show full opinionHide full opinion
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
TOP PICK
TOP PICK
May 6, 2019
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
Show full opinionHide full opinion
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
HOLD
HOLD
May 3, 2019
Diversity is key in the space. Has a lot of small caps, so will increase volatility. If you can buy a basket of large cap biotechs, that would be the way to go right now. In this space, buy the basket is the most prudent way to go. Individual names bring high risk.
Show full opinionHide full opinion
Diversity is key in the space. Has a lot of small caps, so will increase volatility. If you can buy a basket of large cap biotechs, that would be the way to go right now. In this space, buy the basket is the most prudent way to go. Individual names bring high risk.
TOP PICK
TOP PICK
April 18, 2019
He believes in U.S. biotech which is mostly this ETF (and 10% pharma, plus life sciences). Considering the backdrop of an aging population.
Show full opinionHide full opinion
He believes in U.S. biotech which is mostly this ETF (and 10% pharma, plus life sciences). Considering the backdrop of an aging population.
PAST TOP PICK
PAST TOP PICK
March 7, 2019
(A Top Pick Feb 02/18, Down 3%) Not a bad return given the markets we've had over the last year.
Show full opinionHide full opinion
(A Top Pick Feb 02/18, Down 3%) Not a bad return given the markets we've had over the last year.
PAST TOP PICK
PAST TOP PICK
October 15, 2018

(A Top Pick Nov. 17/17, Up 7%) There was a three for one stock split. This and healthcare are in a long term secular bull market. You have to live with the volatility and this is why he likes the ETF. He would hold it long term.

Show full opinionHide full opinion

(A Top Pick Nov. 17/17, Up 7%) There was a three for one stock split. This and healthcare are in a long term secular bull market. You have to live with the volatility and this is why he likes the ETF. He would hold it long term.

TOP PICK
TOP PICK
September 14, 2018

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

Show full opinionHide full opinion

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

PAST TOP PICK
PAST TOP PICK
August 13, 2018

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

Show full opinionHide full opinion

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

PAST TOP PICK
PAST TOP PICK
June 15, 2018

(A Top Pick September 21 / 2017, Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices.

Show full opinionHide full opinion

(A Top Pick September 21 / 2017, Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices.

Showing 1 to 15 of 66 entries

iShares Nasdaq BioTech ETF(IBB-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 2

Stockchase rating for iShares Nasdaq BioTech ETF is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

iShares Nasdaq BioTech ETF(IBB-Q) Frequently Asked Questions

What is iShares Nasdaq BioTech ETF stock symbol?

iShares Nasdaq BioTech ETF is a American stock, trading under the symbol IBB-Q on the NASDAQ (IBB). It is usually referred to as NASDAQ:IBB or IBB-Q

Is iShares Nasdaq BioTech ETF a buy or a sell?

In the last year, 2 stock analysts published opinions about IBB-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for iShares Nasdaq BioTech ETF.

Is iShares Nasdaq BioTech ETF a good investment or a top pick?

iShares Nasdaq BioTech ETF was recommended as a Top Pick by John Zechner on 2020-07-13. Read the latest stock experts ratings for iShares Nasdaq BioTech ETF.

Why is iShares Nasdaq BioTech ETF stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is iShares Nasdaq BioTech ETF worth watching?

2 stock analysts on Stockchase covered iShares Nasdaq BioTech ETF In the last year. It is a trending stock that is worth watching.

What is iShares Nasdaq BioTech ETF stock price?

On 2020-11-27, iShares Nasdaq BioTech ETF (IBB-Q) stock closed at a price of $143.22.